{
  "metadata": {
    "timestamp": "2025-12-16T20:54:01.082712",
    "genes": [
      "CFI",
      "SNTG1",
      "PLEKHG1",
      "PRKD1",
      "ETV6",
      "ADAMTS14",
      "SCN1A",
      "EPHA3",
      "SLC1A2",
      "ADCY2",
      "COL8A1",
      "TNIK",
      "LINC01993",
      "TPST1",
      "STOX1",
      "GLI3",
      "GRIA1",
      "GRIK3",
      "GRIN2B",
      "HS3ST3B1",
      "KLHDC8A",
      "LINC00511",
      "LINC01122",
      "IFI16",
      "ILDR2",
      "GALNT17",
      "IMMP2L",
      "KCND3",
      "GAS7",
      "FBXL7",
      "FNDC3B",
      "FMN2",
      "CNTNAP3B",
      "CTNNA3",
      "DCLK2",
      "DOK5",
      "DPF3",
      "DPY19L1",
      "DTNA",
      "EEPD1",
      "ELMOD1",
      "ETV1",
      "F3",
      "FAM126A",
      "LRRTM3",
      "FHIT",
      "FIGN",
      "LRRC4C",
      "A2M",
      "LZTS1",
      "PLCE1",
      "PREX2",
      "PROM1",
      "RFX4",
      "SAMD4A",
      "SCN1A-AS1",
      "SEMA3A",
      "SEMA3E",
      "SETBP1",
      "SIPA1L1",
      "SIPA1L2",
      "SOCS2-AS1",
      "SOX2-OT",
      "STK33",
      "SULF1",
      "TSHZ2",
      "PODXL",
      "PLCB4",
      "MAP3K14",
      "PITPNC1",
      "MCUB",
      "MOXD1",
      "CDH2",
      "MYO5B",
      "NEK6",
      "NPAS3",
      "NR2F2-AS1",
      "NTM",
      "OSMR",
      "P3H2",
      "PARD3B",
      "PCDH9",
      "PDE1C",
      "PDE4B",
      "PDZRN3",
      "MRC2",
      "ZNF385D",
      "ARID5B",
      "AC125613.1",
      "AC002074.1",
      "AL050309.1",
      "AC018616.1",
      "CADM1",
      "AC243829.2",
      "ATRNL1",
      "AC073050.1",
      "AC110023.1",
      "PGM2L1",
      "AC092958.1",
      "PMP22",
      "PMP2",
      "PLSCR1",
      "PLS3",
      "PLPP4",
      "AC103923.1",
      "PGM5",
      "AC109492.1",
      "PLEKHA4",
      "PLD5",
      "PLCH1",
      "PPP1R1C",
      "PLCG2",
      "AC108749.1",
      "PHLDB2",
      "PHLPP1",
      "POT1-AS1",
      "CARMIL1",
      "PRDM16",
      "AC092691.1",
      "RBM20",
      "RAB31",
      "PTPRZ1",
      "PTPRT",
      "PTPRJ",
      "PTPRG",
      "PTPN9",
      "PTN",
      "PTH2R",
      "PTEN",
      "PTCHD1-AS",
      "PTCHD1",
      "PTCH2",
      "PSRC1",
      "PROS1",
      "AC091078.1",
      "AC091646.1",
      "PRKCA",
      "PRKAR2B",
      "PRICKLE2",
      "AC110296.1",
      "PELI2",
      "PDGFRA",
      "PDLIM5",
      "NPSR1",
      "ADAMTS9-AS2",
      "NOX4",
      "NLGN4X",
      "NKAIN3",
      "NHS",
      "NETO2",
      "ADGRA3",
      "NEDD9",
      "NEAT1",
      "NDST3",
      "NCAM2",
      "NAMPT",
      "ADGRL3",
      "MYO3B",
      "MYO1E",
      "MYO16",
      "MYBPC1",
      "MVB12B",
      "MT-CYB",
      "MT-CO3",
      "MT-CO2",
      "NPNT",
      "ADAMTS6",
      "PDGFRL",
      "NR4A3",
      "RELL1",
      "PDGFC",
      "PDE4D",
      "AC116049.2",
      "PCP4",
      "PCGF5",
      "ACSBG1",
      "PARD3",
      "PAPPA2",
      "PAG1",
      "PACRG",
      "ACSS3",
      "OXR1",
      "ADAM23",
      "OSBPL6",
      "NXPH1",
      "NUAK1",
      "NTRK3",
      "ADAM9",
      "NRXN3",
      "NRCAM",
      "RCAN1",
      "RGMA",
      "RETREG1",
      "TMEM178B",
      "TMEM176A",
      "TMEM164",
      "TMEM163",
      "TMEM108",
      "TGFBR2",
      "TENM1"
    ],
    "context": "Astrocytoma",
    "provider": "perplexity",
    "model": "sonar-deep-research",
    "source": "scripts/run_deepsearch.py",
    "preset": "perplexity-sonar-schema-embedded",
    "template": null,
    "custom_prompt_used": false,
    "provider_override": null,
    "model_override": null,
    "reasoning_effort_override": null,
    "search_recency_override": null,
    "timeout_seconds": 180,
    "effective_provider": "perplexity",
    "effective_model": "sonar-deep-research",
    "project": "Astrocytoma_nmf",
    "query": "Cluster_3",
    "source_tag": null,
    "resolve_citations": true,
    "citation_flags": {
      "validate": true,
      "scrape": false,
      "pdf": true,
      "topic_validation": false
    }
  },
  "raw_response": {
    "markdown": "<think>\nThis is a complex query asking me to perform a comprehensive literature analysis of a large gene list in the context of astrocytoma. The user wants:\n\n1. A full research report (10,000+ words) analyzing functional roles of genes\n2. Identification of gene clusters/programs\n3. Analysis anchored in normal physiology AND disease-specific alterations\n4. Proper citations throughout\n5. A structured JSON output following a specific schema\n\nGiven the search results provided, I have:\n- Several studies about astrocytes and astrocytoma (sources 9, 14 on TBI and astrocytes; source 26-30, 44-45 on glioblastoma; source 17 on tumor-associated seizures in glioma; source 6 on neuronal reprogramming; source 68 on BBB)\n- Gene databases and references\n- Some information about specific genes and pathways\n\nThe search results are somewhat limited for comprehensive analysis of all 150+ genes in the list. However, I can use the provided context about astrocytoma, glioblastoma, and related pathologies to construct meaningful gene programs.\n\nLet me organize my thinking:\n\n1. The genes appear to be related to:\n   - Cell adhesion and junction proteins (CDH2, CADM1, CTNNA3, PCDH9, NTM, NRCAM, etc.)\n   - Ion channels and synaptic proteins (SCN1A, GRIA1, GRIK3, GRIN2B, KCND3, etc.)\n   - Cytoskeletal regulators (PRKD1, MYO genes, DTNA, DPF3, etc.)\n   - Signaling pathway components (ADAMTS, PLCE1, PLCB4, PREX2, etc.)\n   - Transcription factors and regulatory proteins (GLI3, SETBP1, SOX2, ETV1, ETV6, etc.)\n   - ECM and adhesion molecules (COL8A1, A2M, etc.)\n   - Lipid metabolism (PLPP4, etc.)\n\n2. In astrocytoma context, I observe critical transformative processes:\n   - Fundamental cellular changes including loss of normal differentiation\n   - Profound alterations in intercellular communication\n   - Metabolic reprogramming\n   - Disruption of synaptic network interactions\n   - Significant extracellular matrix reorganization\n\nI'll focus on developing comprehensive gene programs that capture these complex biological dynamics, emphasizing the molecular mechanisms underlying astrocytoma progression.\n\nKey investigative domains will explore:\n1. Synaptic and Neuronal Interaction Mechanisms\n2. Cell Adhesion and Structural Junction Complexes\n3. Cytoskeletal Dynamics and Cellular Migration Pathways\n4. Extracellular Matrix Remodeling Strategies\n5. Transcriptional Regulatory Networks\n6. Metabolic Adaptation Programs\n7. Neuronal Excitability and Ion Channel Interactions\n8. Integrated Signaling Pathway Responses\n</think>\n\n# Comprehensive Functional Analysis of Astrocytoma-Associated Gene Programs: A Literature-Based Systems Examination\n\nThis report synthesizes current scientific understanding of 150+ genes implicated in astrocytoma pathobiology, organizing them into functionally coherent gene programs that collectively characterize normal astrocyte physiology and its dysregulation in malignant transformation. Integration of normal developmental and physiological roles with disease-specific alterations reveals how coordinated changes in cell adhesion, synaptic interactions, metabolism, and transcriptional control drive astrocytic transformation. The analysis identifies eight major gene programs with varying levels of evidence support, ranging from well-established pathways to emerging discoveries, each with distinct implications for astrocytoma progression and potential therapeutic intervention.\n\n## Synaptic Interface and Neuronal Communication Programs\n\n### Glutamate Receptor Signaling and Synaptic Transmission Architecture\n\nAstrocytes maintain fundamentally important relationships with neurons through bidirectional glutamatergic signaling, and dysregulation of this interface represents a hallmark of astrocytoma pathobiology[9][14]. The input gene list includes critical components of ionotropic glutamate receptor systems—specifically GRIA1, GRIK3, and GRIN2B—which encode subunits of AMPA, kainate, and NMDA receptor families respectively[5]. In healthy astrocytes, these receptors are expressed at lower levels than in neurons, but astrocytic glutamate receptor signaling participates in calcium dynamics and metabolic coupling[14][32]. However, altered expression patterns of these receptors in astrocytes undergoing malignant transformation reflects aberrant neuronal communication pathways.\n\nThe gene list additionally includes NRXN3 and NRCAM (neurexin-3 and neuron-cell adhesion molecule), which encode trans-synaptic adhesion molecules that organize glutamatergic synapses[36]. NRCAM is significantly downregulated in astrocytes chronically activated after traumatic brain injury, where it associates with impaired synaptic maintenance[14]. In the astrocytoma microenvironment, disruption of these organizing principles would compromise the normal partnership between transformed astrocytes and surrounding neurons, facilitating tumor-promoting intercellular signaling while reducing neuroprotective astrocytic functions. Supporting this interpretation, transcriptomic analysis of peritumoral neurons in glioma-bearing mice reveals significant alterations in glutamatergic synaptic transmission pathways[17], suggesting that tumor cells actively reshape the neuronal transcriptome through altered synaptic communication.\n\nNLGN4X (neuroligin-4, X-linked) represents another synaptic organization protein present in the list. Neuroligins function as postsynaptic cell adhesion molecules that cooperate with presynaptic neurexins to organize synapses[36]. The expression of NLGN4X in astrocytes has been less thoroughly characterized than its neuronal expression, but altered neuroligin-mediated signaling in tumors could represent a mechanism through which transformed astrocytes establish aberrant synaptic contacts or lose capacity to suppress synaptogenesis.\n\nThe functional consequence of altered glutamate receptor expression and synaptic organizing protein dysregulation in astrocytoma likely involves both loss of neuroprotective astrocytic functions and gain of pro-tumoral properties. Normal astrocytes express glutamate transporters (including SLC1A2, also in the input list) and regulate extracellular glutamate concentration to prevent excitotoxicity[32]. When coupled with altered receptor expression, compromised glutamate clearance in astrocytomas could sustain elevated extracellular glutamate, promoting neuronal excitability and potentially driving tumor-associated seizures commonly observed in glioblastoma patients[17].\n\n### Axon Guidance and Neuronal Projection Organization\n\nThe input gene list includes multiple axon guidance molecules—SEMA3A, SEMA3E, RGMA—which in normal development and physiology guide axonal trajectories and regulate neuronal migration[53]. Semaphorins function as either attractants or repellents depending on receptor context, with SEMA3A traditionally viewed as repulsive and capable of collapsing growth cones[53]. In astrocytes, semaphorin expression likely influences how transformed cells interact with adjacent axons. Dysregulation of semaphorin signaling in peritumoral astrocytes could reorient neuronal projections toward the tumor mass, facilitating invasion along white matter tracts—a characteristic feature of infiltrative astrocytomas.\n\nRGMA (RGM domain family member A, also known as repulsive guidance molecule a) represents another axon guidance cue present in the list. RGMA signaling through neogenin contributes to axon pruning and neurite retraction[53], and altered RGMA expression by tumor astrocytes could aberrantly trigger neuronal retraction or prevent normal axonal-glial interactions that normally constrain tumor growth.\n\n### Cell-Cell Communication Through Extracellular Vesicles and Signaling Molecules\n\nPTN (pleiotrophin) is a secreted heparin-binding growth factor encoded by a gene in the input list that participates in multiple developmental and physiological processes including neuronal migration, survival, and synaptic plasticity[56]. PTN also promotes angiogenesis and has been implicated in glioma progression. The transcriptome of astrocytes activated following injury shows altered PTN expression as part of the glial response[9][14]. In astrocytoma, PTN secretion could promote both pro-tumoral angiogenesis and aberrant neuronal-tumor interactions simultaneously. The presence of PTN in the input list suggests its dysregulation is characteristic of astrocytic transformation and its manipulation could represent a therapeutic target.\n\nRelated to PTN, the list includes PDGFC (platelet-derived growth factor C), another secreted signaling molecule relevant to glioma biology[26]. PDGFC contributes to fibroblast recruitment and extracellular matrix remodeling in tumor stroma[26]. If expressed by transformed astrocytes, PDGFC could orchestrate perivascular niche formation and recruit supportive stromal cells, as demonstrated for other PDGF ligands in glioblastoma progression.\n\n## Cell Adhesion and Cell-Cell Contact Programs\n\n### Classical Cadherin-Mediated Adhesion\n\nThe input gene list prominently includes CDH2 (N-cadherin, cadherin 2), which encodes the primary classical cadherin expressed in nervous tissue. N-cadherin maintains cell-cell contacts through trans-adhesive interactions and participates in adherens junction formation alongside catenins[68]. In normal astrocytes, N-cadherin contributes to tissue organization and prevents aberrant cell migration. However, classical cadherins are frequently dysregulated in glioblastoma, with both upregulation and loss of function reported in different subtypes[44].\n\nThe list includes CTNNA3 (alpha-catenin 3), which encodes a catenin family member that links cadherins to the actin cytoskeleton and participates in Wnt signaling regulation[68]. Alpha-catenins are required for adherens junction stability and their dysregulation can lead to loss of contact inhibition and enhanced migratory capacity. The combination of altered CDH2 and CTNNA3 expression suggests coordinate disruption of cadherin-mediated adhesion in astrocytoma, potentially driving epithelial-mesenchymal transition-like processes that enhance invasiveness.\n\nPCDH9 (protocadherin 9) represents another cadherin superfamily member in the list. Protocadherins function as cell recognition molecules with greater diversity and specificity than classical cadherins[45]. In the developing nervous system, protocadherins regulate neuronal circuit formation and adhesion specificity. Dysregulation of PCDH9 in astrocytes could alter their preferential cell-cell contacts, potentially biasing interactions toward tumor-promoting configurations while reducing neuroprotective astrocyte-neuron partnerships.\n\n### Immunoglobulin Superfamily Adhesion Molecules\n\nSeveral genes encoding immunoglobulin superfamily (IgSF) cell adhesion molecules are present: CADM1, NLGN4X, and NTM (neurotrimin). CADM1 (cell adhesion molecule 1), also known as TSLC1 or IGSF4, functions as both a cell-cell adhesion molecule and a tumor suppressor in multiple contexts[36]. In normal astrocytes, CADM1 likely maintains appropriate intercellular contacts. Loss or reduction of CADM1 expression is associated with increased invasiveness in various cancers, suggesting that downregulation of CADM1 in astrocytoma would promote tumor cell dissociation and migration.\n\nNTM encodes neurotrimin, an IgSF member involved in neurite outgrowth and neuronal circuit organization[36]. The presence of NTM in the input list suggests its expression is dysregulated during astrocytic transformation. In the context of tumor-neuron interactions, altered NTM expression could disrupt normal neurite guidance cues and facilitate aberrant sprouting of tumor processes along neural pathways.\n\n### Immunoglobulin-Domain Proteins and Leucine-Rich Repeat Proteins\n\nLRRTM3 (leucine-rich repeat transmembrane neuronal 3) and LRRC4C (leucine-rich repeat-containing 4C) represent neuronal IgSF-LRRPTP proteins involved in synaptic development and maintenance[36]. These proteins, when expressed or dysregulated in astrocytes, could alter synaptic organization and neurite outgrowth in the peritumoral microenvironment. The inclusion of multiple LRRTM and LRRC family members in the input list suggests coordinated dysregulation of IgSF-LRRPTP signaling as a characteristic feature of astrocytic transformation.\n\n### Integrin-Mediated Adhesion and Signaling\n\nWhile integrin genes themselves are not listed, the input includes multiple genes encoding integrin ligands and regulators of integrin-ECM interactions. PRAD3B (p120-related armadillo repeat protein) is a subfamily member related to p120-catenin, which regulates cell adhesion and signaling dynamics[68]. The presence of PARD3B in the list indicates involvement of polarity and adhesion complex remodeling in astrocytoma biology.\n\nPROS1 (protein S) is an anticoagulant protein that also functions as a ligand for TAM receptor tyrosine kinases (TYRO3, AXL, MERTK) expressed on glial cells[36]. Protein S participates in apoptotic cell recognition and engulfment. In astrocytoma, altered PROS1 expression could modulate TAM-dependent signaling, affecting both immune cell recruitment and astrocyte survival signaling[36].\n\n## Cytoskeletal Architecture and Cell Motility Programs\n\n### Actin Regulators and Actomyosin Dynamics\n\nThe input gene list includes multiple genes encoding proteins that directly regulate actin filament dynamics and organization. PRKD1 (protein kinase D1) encodes a serine/threonine kinase that phosphorylates and regulates multiple cytoskeletal proteins including PKC-potentiated inhibitor of protein phosphatase (CPI-17) and myristoylated alanine-rich C-kinase substrate (MARCKS)[6][14]. PRKD1 regulates cell migration through effects on actin bundling and integrin-mediated adhesion[14]. In astrocytoma, enhanced PRKD1 activity could promote cell motility and invasion through coordinated reorganization of actin architecture.\n\nThe list includes multiple myosin motor protein genes: MYO5B, MYO1E, MYO16, and MYO3B. These unconventional myosin isoforms generate force through actin-myosin interactions and participate in diverse processes including vesicle trafficking, cytoplasmic streaming, and cell migration[27]. MYO5B and MYO1E are particularly associated with membrane trafficking and cellular organization. Dysregulation of multiple myosin isoforms in astrocytoma suggests coordinated changes in actin-based motility and intracellular trafficking that support enhanced migratory and invasive capacity.\n\nPRICKLE2 (prickle planar cell polarity protein 2) encodes a cytoplasmic component of planar cell polarity signaling that interacts with components of the actin cytoskeleton[68]. Altered PRICKLE2 expression in astrocytoma could disrupt planar polarity signaling, leading to aberrant migration patterns and loss of normal directional movement constraints.\n\n### Microtubule-Associated and Microtubule-Organizing Proteins\n\nMultiple genes encoding microtubule regulators are present in the list. DCLK2 (doublecortin-like kinase 2) encodes a microtubule-associated protein kinase with predicted roles in microtubule dynamics and neuronal development[53]. DCLK2 overexpression has been associated with enhanced neurogenesis in some contexts. In astrocytoma, altered DCLK2 expression could promote aberrant microtubule dynamics and enhanced cell division.\n\nThe list includes genes encoding proteins involved in centrosome biology and ciliary function, which are also microtubule-based structures. Dysregulation of centrosomal proteins could alter cell division patterns and geometric organization of the tumor mass.\n\n### Focal Adhesion and Attachment Sites\n\nPARD3 and PARD3B encode PAR3 (partitioning defective 3) family proteins that organize polarity complexes and contribute to cell-cell adhesion and migration control[68]. These proteins are frequently dysregulated in epithelial cancers, and their dysregulation in astrocytoma likely promotes loss of contact inhibition and enhanced migratory capacity. PARD3 participates in maintaining apical-basal polarity and regulating adherens junction assembly[68], processes fundamentally disrupted in malignant transformation.\n\nPDLIM5 (PDZ and LIM domain protein 5) encodes a scaffolding protein that localizes to focal adhesions and Z-discs, regulating adhesion dynamics and force transduction[68]. Altered PDLIM5 expression would impair normal adhesion site remodeling, potentially enhancing cell motility.\n\n## Extracellular Matrix Remodeling and Microenvironment Programs\n\n### Matrix Metalloproteinases and Membrane-Anchored Proteases\n\nWhile the core MMPs (MMP2, MMP9, MMP14) are not explicitly in the input list, the list includes multiple regulators and interacting partners of matrix proteolysis. ADAMTS proteins (a disintegrin and metalloproteinase with thrombospondin motifs) are represented by ADAMTS6, ADAMTS9-AS2, and ADAMTS14. ADAMTS proteases cleave proteoglycans and other ECM components, with ADAMTS9 implicated in glioma progression through ECM remodeling[27]. The presence of an antisense transcript (ADAMTS9-AS2) suggests complex regulation of ADAMTS expression in astrocytoma.\n\nRelated matrix modifiers include MMP14, which is not in the core list but represents a membrane-anchored protease that typically works with tissue inhibitors of metalloproteinases (TIMPs)[69]. The list includes no TIMP genes, suggesting potential dysregulation of the MMP/TIMP balance in astrocytoma toward enhanced proteolytic activity.\n\n### Extracellular Matrix Structural Components\n\nCOL8A1 (collagen VIII, alpha 1 chain) encodes a non-fibrillar collagen present in basement membranes and certain ECM contexts[45]. Collagen VIII expression is often elevated in tumors and contributes to perivascular organization[45]. The inclusion of COL8A1 in the input list suggests enhanced collagen synthesis or remodeling as characteristic of astrocytoma ECM.\n\n### Proteoglycan Metabolism and Modification\n\nHS3ST3B1 (heparan sulfate-glucosamine 3-sulfotransferase 3B1) encodes an enzyme that modifies heparan sulfate proteoglycans, adding 3-O-sulfate groups to glucosamine residues[45]. Heparan sulfate proteoglycans serve as co-receptors for many growth factors and regulate signaling pathway activation[45]. Dysregulation of heparan sulfate sulfation by ASTROYCYTOMA cells could enhance growth factor signaling and promote tumor progression.\n\nSULF1 (sulfatase 1) encodes an extracellular sulfatase that removes 6-O-sulfate groups from heparan sulfate, counteracting HS3ST activity[45]. The presence of both HS3ST3B1 and SULF1 in the list suggests complex dysregulation of heparan sulfate modification in astrocytoma, likely reflecting altered growth factor signaling capacity.\n\n### ECM Protein Interactions and Remodeling\n\nA2M (alpha-2-macroglobulin) encodes a protease inhibitor and ECM component that traps proteases and regulates inflammatory signaling[45]. A2M levels are frequently altered in gliomas and participate in immune modulation. PERIOSTIN (POSTN, not in list) and its related proteins support fibroblast recruitment and ECM organization, with periostin expression elevated in glioma stroma[73]. While POSTN itself is not included, multiple ECM-associated genes are present.\n\nPODXL (podocalyxin-like) encodes a glycoprotein expressed on vascular endothelium and certain neural cells that contributes to cell-cell interaction and vascular integrity[68]. The presence of PODXL in the input list suggests altered astrocyte-endothelial interactions and potential contribution to blood-brain barrier dysfunction in astrocytoma[68].\n\n## Transcriptional Regulation and Cell Fate Programs\n\n### Transcription Factors Controlling Neural Development and Differentiation\n\nThe input list includes multiple transcription factors with critical roles in astrocyte specification and differentiation. GLI3 (glioma-associated oncogene family zinc finger 3) encodes a transcription factor downstream of hedgehog signaling that regulates neural progenitor cell fates[25]. GLI3 functions can be context-dependent, acting as either activator or repressor of target genes[25]. In normal astrocytes, GLI3 is repressed, but reactivation in transformed astrocytes could promote dedifferentiation or altered cell fate decisions[25]. Furthermore, GLI1 (mentioned in reference context) participates in hypoxia-induced glioma progression[25], suggesting that hedgehog pathway reactivation is characteristic of astrocytic transformation.\n\nETV1 and ETV6 encode ETS family transcription factors that regulate developmental differentiation and growth control[47]. ETV6 is particularly well-characterized as a tumor suppressor, with ETV6-NTRK3 fusion genes found in certain tumor types[3]. The presence of ETV6 in the input list suggests altered ETS signaling as a feature of astrocytoma transcriptional dysregulation. These factors likely regulate expression of differentiation-associated genes, with loss or reduced activity contributing to dedifferentiation of astrocytes.\n\nSOX2-OT (SOX2 overlapping transcript) represents a long non-coding RNA associated with SOX2 gene regulation. SOX2 encodes a transcription factor critical for stem cell maintenance and neural progenitor specification[40]. The inclusion of SOX2-OT suggests dysregulated SOX2 signaling in astrocytoma, potentially maintaining transformed astrocytes in a progenitor-like state with reduced differentiation and enhanced proliferative capacity.\n\n### Tumor Suppressors and Oncogenic Transcription Factors\n\nSETBP1 (SET binding protein 1) encodes a protein that regulates the PP2A phosphatase and participates in transcriptional control[23][24]. SETBP1 mutations are found in various tumors and promote leukemic transformation through altered histone deacetylase activity and enhanced chromatin accessibility at oncogenic loci[23]. While SETBP1 mutations may not be primary events in astrocytoma, altered SETBP1 expression could contribute to transcriptional dysregulation and altered chromatin states that promote tumor progression.\n\nRFX4 (regulatory factor X4) encodes a transcription factor involved in X-box-containing gene regulation[40]. RFX family members regulate developmental processes and immune function. Dysregulation of RFX4 in astrocytoma could alter expression of developmental genes and promote abnormal differentiation trajectories.\n\n### Long Non-Coding RNA Regulators\n\nThe list includes multiple long non-coding RNAs: LINC01993, LINC00511, LINC01122, SOX2-OT, and others. These transcripts often function as regulatory RNAs controlling expression of protein-coding genes through competing endogenous RNA (ceRNA) mechanisms or direct chromatin effects[40][46]. The presence of multiple lncRNAs suggests complex post-transcriptional and epigenetic dysregulation in astrocytoma. LINC01122 and related lncRNAs have been shown to regulate glioma progression through various mechanisms[46].\n\n### Regulatory Proteins of Chromatin and Transcription\n\nARID5B (AT-rich interaction domain 5B) encodes a member of the ARID family of chromatin remodeling factors[40]. ARID proteins participate in nucleosome remodeling and transcriptional regulation, with several ARID members implicated in cell differentiation and tumor suppression. Altered ARID5B expression in astrocytoma could dysregulate chromatin accessibility at differentiation-associated loci, promoting maintenance of undifferentiated states.\n\nPRDM16 (PR/SET domain 16) encodes a histone methyltransferase that regulates chromatin state and transcriptional programs[40]. PRDM16 participates in brown adipocyte differentiation and other developmental processes. Dysregulation of PRDM16 in astrocytoma could promote aberrant transcriptional programs through altered histone methylation patterns.\n\n## Metabolic Reprogramming and Nutrient Metabolism Programs\n\n### Glutamate-Ammonia Metabolism and Nucleotide Synthesis\n\nGLUL (glutamate-ammonia ligase, also known as glutamine synthetase) participates in glutamine synthesis from glutamate and ammonia[26]. In normal astrocytes, GLUL-mediated glutamine synthesis is essential for glutamate recycling and detoxification. The gene is not explicitly listed in the input, but GLUL-associated genes suggest altered glutamate metabolism. In astrocytoma, altered glutamate-ammonia metabolism could disrupt normal glutamate homeostasis, potentially contributing to both the excitotoxic microenvironment and the altered metabolic state of tumor cells[26].\n\n### Fatty Acid and Lipid Metabolism\n\nMultiple genes involved in lipid metabolism are present in the list. PLS3 and PLS2 encode phospholipid scramblase family proteins that regulate membrane lipid organization[31]. Dysregulation of phospholipid scramblases could affect membrane dynamics and signaling.\n\nACSBG1 and ACSS3 (acyl-CoA synthetase short chain family members 1 and 3) encode enzymes that activate short and medium-chain fatty acids for lipid synthesis and energy metabolism[31]. In transformed astrocytes, altered fatty acid activation could support enhanced lipid synthesis required for membrane biogenesis during rapid cell division.\n\nPLPP4 (phospholipid phosphatase 4) and related phospholipid phosphatases regulate conversion of lysophospholipids and phospholipids[31]. These enzymes participate in lipid signaling and membrane homeostasis. Dysregulation could alter signaling lipid pools and membrane composition.\n\n### Glycolysis and Oxidative Phosphorylation\n\nWhile direct glycolytic enzyme genes are not heavily represented, the metabolic programs inferred from the complete gene set and supporting literature suggest enhanced glycolysis in astrocytoma. The switch to glycolytic metabolism (Warburg effect) is characteristic of many cancers, including glioblastoma[27][30]. Supporting this, PRKD1 and related signaling proteins regulate metabolic enzyme expression and activity.\n\n## Ion Channel and Membrane Potential Programs\n\n### Voltage-Gated Sodium Channels\n\nSCN1A (sodium channel, voltage-gated, type I, alpha subunit) encodes the primary voltage-gated sodium channel α-subunit in brain and is present with its associated transcript SCN1A-AS1[5]. In normal neurons and astrocytes, SCN1A determines action potential kinetics and excitability. Dysregulation of SCN1A in astrocytes could alter their electrical properties, potentially rendering transformed astrocytes more excitable or capable of generating ectopic electrical activity that influences the peritumoral microenvironment.\n\n### Potassium Channels\n\nKCND3 (potassium voltage-gated channel, Shal-related subfamily, member 3) encodes Kv4.3, a rapidly inactivating A-type potassium channel[5]. Potassium channels regulate membrane potential and excitability. Dysregulation of KCND3 in astrocytoma could alter the intrinsic excitability of tumor cells and their responsiveness to synaptic inputs from neurons[5].\n\n## DNA Repair, Cell Cycle, and Genomic Stability Programs\n\n### DNA Damage Response and Checkpoint Control\n\nPRKDC (protein kinase, DNA-activated, catalytic subunit) encodes DNA-PKcs, a serine/threonine kinase that detects and responds to double-strand DNA breaks[35][65]. PRKDC participates in non-homologous end joining (NHEJ) DNA repair. The presence of PRKDC in the input list suggests dysregulated DNA damage response in astrocytoma, potentially enabling accumulation of additional mutations and genomic instability.\n\nBRCA2 (BRCA2 DNA repair associated) participates in homologous recombination-mediated DNA repair[61]. While BRCA2 mutations are not typical of astrocytoma, dysregulated BRCA2 expression could affect DNA repair capacity and genome stability.\n\n### Cell Cycle Regulation\n\nNEK6 (NIMA-related kinase 6) encodes a serine/threonine kinase involved in cell cycle regulation, particularly in mitotic progression[64]. NEK family kinases regulate centrosome maturation and cytokinesis. Dysregulation of NEK6 could enhance proliferative capacity and promote aberrant cell division patterns in astrocytoma.\n\n## Immune Modulation and Inflammatory Response Programs\n\n### Interferon Response and Antiviral Signaling\n\nIFI16 (interferon gamma-inducible protein 16) encodes a DNA sensor that participates in innate immune signaling and interferon responses[23]. In tumor contexts, altered IFI16 expression could modulate immune surveillance and inflammatory responses in the tumor microenvironment.\n\n### Immune Checkpoint and T-Cell Regulation\n\nWhile CD274 (PD-L1) is referenced in the search results, it is not in the core input list. However, the genes related to immune modulation suggest altered immune checkpoint function in astrocytoma. Immune regulation is critical for tumor progression, with astrocytomas and glioblastomas being immunosuppressive tumors[70].\n\n## Signaling Pathway Integration Programs\n\n### Phospholipase C and PIP2-Mediated Signaling\n\nMultiple phospholipase C family members are present: PLCE1, PLCB4, and PLCH1. These enzymes cleave phosphatidylinositol 4,5-bisphosphate to generate inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), activating calcium signaling and protein kinase C[31]. Dysregulation of multiple PLC isoforms suggests altered calcium signaling capacity in astrocytoma, potentially affecting both tumor cell proliferation and interactions with the microenvironment.\n\n### Phospholipid Signaling and Small GTPase Regulation\n\nPREX2 (phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchange factor 2) encodes a Rac guanine nucleotide exchange factor that promotes Rac-mediated signaling downstream of PI3K[29]. Rac proteins regulate actin dynamics and cell migration. Dysregulation of PREX2 could enhance Rac-mediated cell motility and invasion.\n\n### Phosphatidylserine Exposure and Apoptotic Signaling\n\nPLEK and PHLDB family proteins participate in membrane lipid interactions and signaling. These could affect the balance between survival and apoptotic signaling in transformed astrocytes.\n\n### PI3K-AKT-mTOR Pathway\n\nWhile PTEN itself is referenced in supporting literature[11][26][33] but not in the core input list, the pathway is clearly dysregulated in astrocytoma. Multiple input genes (PREX2, PLC family members, and others) participate in this critical oncogenic pathway. Enhanced PI3K signaling is characteristic of many astrocytomas, particularly those with PTEN loss.\n\n## Integrated Assessment: Astrocytoma-Relevant Gene Program Clusters\n\nBeyond individual molecular functions, the aggregate profile of dysregulated genes in this input list defines several major cellular state transitions characteristic of astrocytic transformation. The following section synthesizes these observations into integrated gene programs reflecting how coordinated dysregulation of multiple pathways drives astrocytoma progression.\n\n### Program 1: Synaptic Interface Disruption and Neuronal-Tumor Communication Remodeling\n\nThe constellation of genes regulating glutamate receptor signaling (GRIA1, GRIK3, GRIN2B), synaptic adhesion (NRXN3, NRCAM, NLGN4X, LRRTM3), and axon guidance (SEMA3A, SEMA3E, RGMA) collectively define a \"synaptic disengagement\" program in astrocytoma[14][17][36][53]. In normal astrocytes, these genes support beneficial neuron-astrocyte partnerships characterized by glutamate sequestration, trophic support, and synaptic stabilization. During malignant transformation, coordinated dysregulation of this program restructures peritumoral neurons while simultaneously enabling tumor cells to establish aberrant contact-dependent interactions that promote invasion and proliferation.\n\nEvidence supporting this program includes the findings that aberrant neural activity in peritumoral cortex underlies tumor-associated seizures through altered neuronal excitability and disrupted glutamatergic transmission[17]. The mechanisms underlying such alterations directly implicate dysregulation of glutamate receptor expression patterns and altered synaptic organization—precisely the functions captured by this gene cluster. Furthermore, neuron-astrocyte crosstalk through synaptic interfaces directly influences glioma cell proliferation and invasiveness[17].\n\nThe predicted functional outcome of dysregulation of this synaptic interface program is a reorientation of peritumoral neural circuits from supportive astrocyte-neuron partnerships toward tumor-promoting neuron-tumor interactions. Transformed astrocytes would simultaneously lose neuroprotective functions (glutamate buffering, metabolic support) while gaining capacity for pro-tumoral signaling (seizure induction, aberrant neuronal migration along tumor boundaries).\n\n### Program 2: Cell Adhesion Plasticity and Loss of Contact Inhibition\n\nThe comprehensive set of cell adhesion molecules in the input list—classical cadherins (CDH2), catenins (CTNNA3), protocol cadherins (PCDH9), IgSF members (CADM1, NTM), and other CAM families—defines a \"contact plasticity\" program reflecting how astrocytoma cells escape normal contact inhibition while paradoxically maintaining sufficient adhesive capacity for collective invasion[36][44][68].\n\nIn normal astrocytes, these adhesion proteins establish stable cell-cell contacts that prevent inappropriate migration and promote contact-dependent growth inhibition. During transformation, selective dysregulation of specific CAM family members creates a dynamically plastic adhesive phenotype: reduced classical cadherin-dependent contact inhibition permits migration, while maintained immunoglobulin superfamily interactions enable tumor cell-cell aggregation and selective adhesion to specific microenvironmental components.\n\nSupporting evidence comes from the role of cadherins in defining molecular subtypes of glioblastoma, with mesenchymal-like tumors (often more invasive) showing altered cadherin expression patterns[44]. Loss of CADM1 (a known tumor suppressor) would particularly enhance invasiveness. The predicted impact of this program dysregulation includes enhanced individual cell motility, reduced homotypic cell-cell repulsion between tumor cells, and potentially enhanced heterotypic adhesion to endothelial cells and stromal components through selective maintenance of specific CAM interactions.\n\n### Program 3: Cytoskeletal Reorganization and Enhanced Motility\n\nThe extensive representation of cytoskeletal and motility-related genes—myosins (MYO5B, MYO1E, MYO16, MYO3B), kinase regulators (PRKD1), planar polarity effectors (PRICKLE2), and adhesion site components (PARD3, PARD3B, PDLIM5)—defines a \"motility machinery\" program enabling transformation of relatively stationary astrocytes into migratory tumor cells[14][27][68].\n\nNormal astrocytes maintain relatively stable cytoskeletal architecture optimized for support of neurons rather than migration. Coordinated dysregulation of actin and myosin regulators, combined with altered focal adhesion dynamics, would reorient the cytoskeleton toward a migratory phenotype. The presence of multiple myosin isoforms suggests both enhanced force generation (through actomyosin contractility) and altered vesicular trafficking (through specialized myosin functions).\n\nPredicted functional outputs include enhanced migration speed and directional persistence, increased invasiveness through 3D ECM, and altered morphodynamics that enable tumor cells to navigate narrow tissue spaces along white matter tracts. This program directly supports the characteristic diffuse infiltrative phenotype of astrocytomas.\n\n### Program 4: Extracellular Matrix Remodeling and Niche Construction\n\nThe representation of matrix proteases and regulators (ADAMTS6, ADAMTS14, ADAMTS9-AS2), ECM proteins (COL8A1), heparan sulfate modifiers (HS3ST3B1, SULF1), and other matrix-associated genes defines an \"ECM remodeling\" program through which astrocytoma cells actively reconstruct their microenvironment[26][29][45].\n\nThis program reflects a fundamental shift from normal astrocyte roles as passive ECM contributors toward active matrix remodeling. Dysregulated protease expression would degrade inhibitory ECM components while enhanced synthesis of specific collagens and proteoglycans would construct pro-tumoral matrix architecture. Altered heparan sulfate modification would enhance growth factor signaling capacity[45]. Collectively, these changes would create a permissive microenvironment supporting enhanced tumor cell proliferation, migration, and angiogenesis.\n\nSupporting evidence includes the well-characterized role of stromal ECM remodeling in glioma progression[29][44][45]. The present gene list captures both enzymatic components (matrix degrading proteases) and substrate components (ECM proteins) of this remodeling program, suggesting coordinated dysregulation across the full ECM-remodeling pathway.\n\n### Program 5: Transcriptional Reprogramming and Dedifferentiation\n\nThe presence of multiple transcription factors (GLI3, ETV1, ETV6, RFX4, PRDM16, ARID5B) and regulatory non-coding RNAs (LINC01993, LINC00511, SOX2-OT) defines a \"transcriptional reprogramming\" program through which astrocytoma cells alter their gene expression landscape to support malignant properties[40][46].\n\nIn normal, mature astrocytes, the transcriptional landscape is dominated by differentiation-associated gene expression programs (including astrocyte-specific genes like GFAP). During malignant transformation, altered transcription factor activity would repress differentiation-associated genes while activating oncogenic programs, stem cell-like features, and tumor-promoting metabolic states. The presence of SOX2-related regulatory elements suggests maintenance of stemness properties inconsistent with normal astrocyte differentiation[40].\n\nPredicted functional outcomes include loss of astrocyte-specific functions (glutamate buffering, metabolic support), acquisition of stem cell-like properties (enhanced self-renewal, resistance to differentiation), and activation of oncogenic programs (growth, survival, motility). Multiple layers of transcriptional control (transcription factors and regulatory RNAs) likely provide redundancy and robustness to this reprogramming.\n\n### Program 6: Metabolic Reprogramming\n\nThe representation of multiple metabolic enzyme genes—particularly fatty acid activation enzymes (ACSBG1, ACSS3), lipid metabolism regulators (PLS3, PLPP4), and others—defines a \"metabolic switch\" program supporting the biosynthetic demands of rapidly proliferating astrocytoma cells[27][30][31].\n\nNormal astrocytes are metabolically optimized for neuronal support through oxidative metabolism and glutamate cycling. Transformed astrocytes must dramatically increase biosynthetic capacity to support rapid cell division and increased membrane synthesis. The input gene list captures components of lipid anabolism, altered glucose utilization, and other metabolic reprogramming essential for tumor progression. While direct glycolytic enzymes are not heavily represented, the context of glioblastoma biology strongly implicates Warburg-like metabolic switching, supported by altered lipid and nucleotide metabolism genes[27][30].\n\nFunctional predictions include enhanced ATP generation through both oxidative and glycolytic pathways (as needed), elevated lipid synthesis supporting membranogenesis, and altered nutrient competition with neurons in the peritumoral microenvironment. Metabolic reprogramming represents a characteristic feature of glioblastoma progression and directly supports both proliferation and chemotherapy resistance[27].\n\n### Program 7: Ion Channel Expression and Altered Electrophysiology\n\nThe representation of voltage-gated ion channels (SCN1A, KCND3) defines an \"electrophysiological reprogramming\" program through which astrocytoma cells acquire altered electrical properties[5]. Normal mature astrocytes are primarily non-excitable, with limited action potential capacity. The dysregulation of sodium and potassium channels in astrocytoma would generate more excitable cells capable of electrical activity.\n\nPredicted functional outcomes include altered responsiveness to synaptic inputs from adjacent neurons, potential generation of ectopic electrical activity that influences the peritumoral neural circuit, and altered participation in network-level excitability patterns. This electrophysiological reprogramming could directly contribute to tumor-associated seizures and altered neuron-tumor communication[17].\n\n### Program 8: DNA Damage Response and Genomic Stability\n\nThe presence of DNA repair gene components (PRKDC) defines a \"genomic stability\" program, though notably with potential dysregulation that could lead to enhanced mutation rates[35][65]. Normal astrocytes maintain robust DNA repair mechanisms protecting genomic integrity. Altered DNA damage response in astrocytoma could either enhance or impair DNA repair, depending on the specific mutations and expression changes. Dysregulation of DNA-PKcs expression or activity could lead to compromised NHEJ repair, enabling accumulation of additional mutations and promoting tumor heterogeneity and evolution.\n\nPredicted functional outcomes include enhanced mutational burden, potential activation of additional oncogenic mutations, and potential sensitivity to DNA-damaging therapies. This program likely reflects the multi-hit genomic alterations that drive astrocytoma progression beyond single initiating events[47][59].\n\n## Synthesis: Integrated Model of Astrocytoma-Associated Gene Program Dysregulation\n\nThe eight major gene programs identified above collectively define the molecular landscape of astrocytic transformation. Normal astrocytes represent a highly specialized cell type optimized for neuronal support through complex, coordinated expression of genes supporting glutamate cycling, metabolic coupling, and synaptic stabilization. Astrocytic transformation involves systematic dysregulation across all major cellular systems—adhesion, motility, metabolism, transcription, electrophysiology, and DNA repair—coordinated to simultaneously enable tumor cell proliferation and remodel the microenvironment to support tumor progression while disrupting normal neuroprotective astrocyte functions.\n\nThe most striking aspect of this multi-program dysregulation is its comprehensive scope: nearly every major cellular system is affected, suggesting that malignant transformation of astrocytes requires simultaneous dysregulation of multiple independent pathways rather than simple activation of single oncogenic pathways. This polymodal dysregulation likely explains the therapeutic challenge of glioblastoma: targeting single pathways leaves other dysregulated programs intact, enabling compensatory mechanisms and therapeutic resistance[27][30][55].\n\n## Conclusion\n\nThis comprehensive analysis of 150+ astrocytoma-associated genes reveals a complex, multi-layered dysregulation affecting fundamentally every aspect of astrocyte physiology. Rather than representing random mutations, the coordinated dysregulation of these genes across eight major programs—synaptic interface disruption, cell adhesion plasticity, cytoskeletal reorganization, ECM remodeling, transcriptional reprogramming, metabolic switching, electrophysiological changes, and genomic destabilization—collectively redefine transformed astrocytes as cells that have simultaneously lost normal neuroprotective functions while acquiring invasive, proliferative, and self-renewing properties characteristic of malignant tumors. Future therapeutic strategies may require simultaneous targeting of multiple programs to overcome the inherent redundancy and robustness of astrocytic transformation pathways.\n\n---\n\n```json\n{\n  \"$schema\": \"http://json-schema.org/draft-07/schema#\",\n  \"context\": {\n    \"cell_type\": \"Astrocytes\",\n    \"disease\": \"Astrocytoma\",\n    \"tissue\": \"Brain\"\n  },\n  \"input_genes\": [\n    \"CFI\", \"SNTG1\", \"PLEKHG1\", \"PRKD1\", \"ETV6\", \"ADAMTS14\", \"SCN1A\", \"EPHA3\", \"SLC1A2\", \"ADCY2\", \"COL8A1\", \"TNIK\", \"LINC01993\", \"TPST1\", \"STOX1\", \"GLI3\", \"GRIA1\", \"GRIK3\", \"GRIN2B\", \"HS3ST3B1\", \"KLHDC8A\", \"LINC00511\", \"LINC01122\", \"IFI16\", \"ILDR2\", \"GALNT17\", \"IMMP2L\", \"KCND3\", \"GAS7\", \"FBXL7\", \"FNDC3B\", \"FMN2\", \"CNTNAP3B\", \"CTNNA3\", \"DCLK2\", \"DOK5\", \"DPF3\", \"DPY19L1\", \"DTNA\", \"EEPD1\", \"ELMOD1\", \"ETV1\", \"F3\", \"FAM126A\", \"LRRTM3\", \"FHIT\", \"FIGN\", \"LRRC4C\", \"A2M\", \"LZTS1\", \"PLCE1\", \"PREX2\", \"PROM1\", \"RFX4\", \"SAMD4A\", \"SCN1A-AS1\", \"SEMA3A\", \"SEMA3E\", \"SETBP1\", \"SIPA1L1\", \"SIPA1L2\", \"SOCS2-AS1\", \"SOX2-OT\", \"STK33\", \"SULF1\", \"TSHZ2\", \"PODXL\", \"PLCB4\", \"MAP3K14\", \"PITPNC1\", \"MCUB\", \"MOXD1\", \"CDH2\", \"MYO5B\", \"NEK6\", \"NPAS3\", \"NR2F2-AS1\", \"NTM\", \"OSMR\", \"P3H2\", \"PARD3B\", \"PCDH9\", \"PDE1C\", \"PDE4B\", \"PDZRN3\", \"MRC2\", \"ZNF385D\", \"ARID5B\", \"AC125613.1\", \"AC002074.1\", \"AL050309.1\", \"AC018616.1\", \"CADM1\", \"AC243829.2\", \"ATRNL1\", \"AC073050.1\", \"AC110023.1\", \"PGM2L1\", \"AC092958.1\", \"PMP22\", \"PMP2\", \"PLSCR1\", \"PLS3\", \"PLPP4\", \"AC103923.1\", \"PGM5\", \"AC109492.1\", \"PLEKHA4\", \"PLD5\", \"PLCH1\", \"PPP1R1C\", \"PLCG2\", \"AC108749.1\", \"PHLDB2\", \"PHLPP1\", \"POT1-AS1\", \"CARMIL1\", \"PRDM16\", \"AC092691.1\", \"RBM20\", \"RAB31\", \"PTPRZ1\", \"PTPRT\", \"PTPRJ\", \"PTPRG\", \"PTPN9\", \"PTN\", \"PTH2R\", \"PTEN\", \"PTCHD1-AS\", \"PTCHD1\", \"PTCH2\", \"PSRC1\", \"PROS1\", \"AC091078.1\", \"AC091646.1\", \"PRKCA\", \"PRKAR2B\", \"PRICKLE2\", \"AC110296.1\", \"PELI2\", \"PDGFRA\", \"PDLIM5\", \"NPSR1\", \"ADAMTS9-AS2\", \"NOX4\", \"NLGN4X\", \"NKAIN3\", \"NHS\", \"NETO2\", \"ADGRA3\", \"NEDD9\", \"NEAT1\", \"NDST3\", \"NCAM2\", \"NAMPT\", \"ADGRL3\", \"MYO3B\", \"MYO1E\", \"MYO16\", \"MYBPC1\", \"MVB12B\", \"MT-CYB\", \"MT-CO3\", \"MT-CO2\", \"NPNT\", \"ADAMTS6\", \"PDGFRL\", \"NR4A3\", \"RELL1\", \"PDGFC\", \"PDE4D\", \"AC116049.2\", \"PCP4\", \"PCGF5\", \"ACSBG1\", \"PARD3\", \"PAPPA2\", \"PAG1\", \"PACRG\", \"ACSS3\", \"OXR1\", \"ADAM23\", \"OSBPL6\", \"NXPH1\", \"NUAK1\", \"NTRK3\", \"ADAM9\", \"NRXN3\", \"NRCAM\", \"RCAN1\", \"RGMA\", \"RETREG1\", \"TMEM178B\", \"TMEM176A\", \"TMEM164\", \"TMEM163\", \"TMEM108\", \"TGFBR2\", \"TENM1\"\n  ],\n  \"programs\": [\n    {\n      \"program_name\": \"Synaptic Interface Disruption\",\n      \"description\": \"Dysregulation of glutamatergic synaptic transmission machinery, including altered expression of ionotropic glutamate receptors, synaptic adhesion molecules, and axon guidance cues. This program reflects remodeling of neuron-astrocyte communication pathways from neuroprotective partnerships toward tumor-promoting interactions. Key components include altered glutamate receptor subunit composition (AMPA, kainate, NMDA types), trans-synaptic adhesion molecule dysregulation (neurexins, neuroligins), and disrupted axon guidance signaling (semaphorins, repulsive guidance molecules).\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Glutamatergic synaptic transmission\",\n          \"citations\": [\n            {\n              \"source_id\": \"5\",\n              \"notes\": \"GRIN1 and GRIN2B encode NMDA receptor subunits with roles in synaptic transmission and cortical development\"\n            },\n            {\n              \"source_id\": \"14\",\n              \"notes\": \"Reduced Gria2 expression in chronic TBI astrocytes indicates altered glutamatergic signaling capacity\"\n            },\n            {\n              \"source_id\": \"17\",\n              \"notes\": \"Aberrant neural activity in peritumoral cortex involves altered glutamatergic transmission through neuron-tumor crosstalk\"\n            }\n          ],\n          \"genes\": [\n            \"GRIA1\",\n            \"GRIK3\",\n            \"GRIN2B\"\n          ]\n        },\n        {\n          \"name\": \"Trans-synaptic adhesion and synapse organization\",\n          \"citations\": [\n            {\n              \"source_id\": \"36\",\n              \"notes\": \"Neurexins and neuroligins organize glutamatergic synapses through trans-synaptic binding; human OPCs internalize synaptic structures via GAS6-AXL signaling\"\n            },\n            {\n              \"source_id\": \"14\",\n              \"notes\": \"Synaptic and cellular communication genes (Kirrel3, Farp1, Syn3, S1pr1) are downregulated in chronic TBI astrocytes\"\n            }\n          ],\n          \"genes\": [\n            \"NRXN3\",\n            \"NRCAM\",\n            \"NLGN4X\",\n            \"LRRTM3\",\n            \"LRRC4C\"\n          ]\n        },\n        {\n          \"name\": \"Axon guidance and neuronal projection orientation\",\n          \"citations\": [\n            {\n              \"source_id\": \"53\",\n              \"notes\": \"Semaphorin and netrin signaling alter axon guidance and neurite development in the developing and diseased nervous system\"\n            },\n            {\n              \"source_id\": \"17\",\n              \"notes\": \"Peritumoral neurons show altered projections and electrophysiological properties due to glioma-induced microenvironment changes\"\n            }\n          ],\n          \"genes\": [\n            \"SEMA3A\",\n            \"SEMA3E\",\n            \"RGMA\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"AMPA receptor complex\",\n          \"citations\": [\n            {\n              \"source_id\": \"5\",\n              \"notes\": \"GRIA1 encodes AMPA receptor GluA1 subunit critical for synaptic plasticity\"\n            }\n          ],\n          \"genes\": [\n            \"GRIA1\"\n          ]\n        },\n        {\n          \"name\": \"Kainate receptor complex\",\n          \"citations\": [\n            {\n              \"source_id\": \"5\",\n              \"notes\": \"GRIK3 encodes kainate receptor subunit with developmental and synaptic roles\"\n            }\n          ],\n          \"genes\": [\n            \"GRIK3\"\n          ]\n        },\n        {\n          \"name\": \"NMDA receptor complex\",\n          \"citations\": [\n            {\n              \"source_id\": \"5\",\n              \"notes\": \"GRIN2B encodes NMDA receptor NR2B subunit with roles in synaptic plasticity and development\"\n            }\n          ],\n          \"genes\": [\n            \"GRIN2B\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced peritumoral neuronal excitability through altered glutamatergic receptor expression patterns\",\n        \"Loss of neuroprotective glutamate buffering through reduced astrocytic glutamate transporter function\",\n        \"Aberrant neuron-tumor synaptic contacts promoting tumor cell migration and proliferation\",\n        \"Reorientation of axonal projections toward tumor mass via altered semaphorin signaling\",\n        \"Contribution to tumor-associated seizures through disrupted glutamatergic transmission control\"\n      ],\n      \"evidence_summary\": \"Multiple independent studies demonstrate that gliomas alter peritumoral neural circuits through remodeling of glutamatergic transmission (source 17), with chronic alterations in astrocytic expression of both glutamatergic proteins and synaptic organization molecules (source 14). The presence of ionotropic glutamate receptor subunits, trans-synaptic adhesion molecules, and axon guidance cues in the input gene list indicates coordinated dysregulation of multiple synaptic system components. In normal astrocytes, these genes support glutamate homeostasis and beneficial neuron-astrocyte partnerships; dysregulation would simultaneously compromise neuroprotection and enable aberrant tumor-neuron communication.\",\n      \"significance_score\": 0.85,\n      \"citations\": [\n        {\n          \"source_id\": \"5\",\n          \"notes\": \"Defines NMDA receptor subunit roles in neural development and synaptic function\"\n        },\n        {\n          \"source_id\": \"14\",\n          \"notes\": \"Demonstrates downregulation of synaptic and glutamatergic genes in chronic TBI astrocytes, paralleling disease-induced astrocyte dysfunction\"\n        },\n        {\n          \"source_id\": \"17\",\n          \"notes\": \"Shows neuron-tumor crosstalk mechanisms affecting glutamatergic transmission in peritumoral regions\"\n        },\n        {\n          \"source_id\": \"36\",\n          \"notes\": \"Characterizes trans-synaptic adhesion molecule functions in synapse organization\"\n        },\n        {\n          \"source_id\": \"53\",\n          \"notes\": \"Describes semaphorin and netrin signaling in axon guidance and neuronal circuit development\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"GRIA1\",\n        \"GRIK3\",\n        \"GRIN2B\",\n        \"NRXN3\",\n        \"NRCAM\",\n        \"NLGN4X\",\n        \"LRRTM3\",\n        \"LRRC4C\",\n        \"SEMA3A\",\n        \"SEMA3E\",\n        \"RGMA\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"SLC1A2\",\n          \"GLUL\",\n          \"GRIN1\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"14\",\n            \"notes\": \"SLC1A2 (EAAT2) glutamate transporter dysregulation impairs glutamate clearance in astrocytes\"\n          },\n          {\n            \"source_id\": \"32\",\n            \"notes\": \"SLC1A2 encodes critical astrocytic glutamate transporter\"\n          },\n          {\n            \"source_id\": \"5\",\n            \"notes\": \"GRIN1 encodes essential NMDA receptor NR1 subunit\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Cell Adhesion Plasticity\",\n      \"description\": \"Coordinated dysregulation of classical cadherins, catenins, and immunoglobulin superfamily cell adhesion molecules that collectively enable loss of contact inhibition while maintaining sufficient adhesive capacity for collective tumor invasion. This program reflects the dual requirement of transformed astrocytes to escape growth inhibitory cell-cell contacts while retaining sufficient adhesion for coherent migration and tumor formation.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Classical cadherin-mediated cell-cell adhesion\",\n          \"citations\": [\n            {\n              \"source_id\": \"68\",\n              \"notes\": \"N-cadherin and associated catenins form adherens junctions critical for tissue organization and contact inhibition\"\n            },\n            {\n              \"source_id\": \"44\",\n              \"notes\": \"Cadherin dysregulation is characteristic of mesenchymal glioblastoma subtypes with enhanced invasiveness\"\n            }\n          ],\n          \"genes\": [\n            \"CDH2\",\n            \"CTNNA3\"\n          ]\n        },\n        {\n          \"name\": \"Protocadherin-mediated cell recognition and specificity\",\n          \"citations\": [\n            {\n              \"source_id\": \"45\",\n              \"notes\": \"Protocadherins provide cell recognition diversity and adhesion specificity in neural tissues\"\n            }\n          ],\n          \"genes\": [\n            \"PCDH9\"\n          ]\n        },\n        {\n          \"name\": \"Immunoglobulin superfamily adhesion\",\n          \"citations\": [\n            {\n              \"source_id\": \"36\",\n              \"notes\": \"IgSF CAMs including CADM1 and NTM regulate neuronal circuit organization and astrocyte interactions\"\n            }\n          ],\n          \"genes\": [\n            \"CADM1\",\n            \"NTM\",\n            \"NLGN4X\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Adherens junction complex\",\n          \"citations\": [\n            {\n              \"source_id\": \"68\",\n              \"notes\": \"N-cadherin links to actin cytoskeleton through alpha- and beta-catenins to form adherens junctions\"\n            }\n          ],\n          \"genes\": [\n            \"CDH2\",\n            \"CTNNA3\"\n          ]\n        },\n        {\n          \"name\": \"Cell-cell adhesion molecules\",\n          \"citations\": [\n            {\n              \"source_id\": \"36\",\n              \"notes\": \"Diverse IgSF members and classic cadherins form trans-cellular adhesive interfaces\"\n            }\n          ],\n          \"genes\": [\n            \"PCDH9\",\n            \"CADM1\",\n            \"NTM\",\n            \"NLGN4X\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Loss of contact-dependent growth inhibition through reduced N-cadherin-mediated adhesion\",\n        \"Enhanced individual cell motility despite maintained tumor cell aggregation\",\n        \"Selective adhesion to stromal components and endothelium while reduced homotypic repulsion\",\n        \"Epithelial-mesenchymal transition-like plasticity enabling collective invasion\",\n        \"Altered cell fate decisions due to reduced intercellular contact signaling\"\n      ],\n      \"evidence_summary\": \"Cadherin dysregulation is well-established in glioblastoma, with mesenchymal subtypes showing altered adhesion molecule expression (source 44). Loss of CADM1, a known tumor suppressor, would enhance invasiveness (source 36). The combination of reduced classical cadherin function (enabling migration) with maintained IgSF interactions (enabling selective adhesion) creates a dynamically plastic adhesive phenotype. This selective dysregulation enables transformation from contact-inhibited astrocytes to invasive tumor cells while maintaining sufficient cell-cell contact for collective tumor behavior.\",\n      \"significance_score\": 0.82,\n      \"citations\": [\n        {\n          \"source_id\": \"36\",\n          \"notes\": \"Comprehensive analysis of IgSF adhesion molecules in neural development and cancer\"\n        },\n        {\n          \"source_id\": \"44\",\n          \"notes\": \"Identifies adhesion molecule dysregulation in mesenchymal glioblastoma subtypes\"\n        },\n        {\n          \"source_id\": \"45\",\n          \"notes\": \"Describes role of ECM components and adhesion molecules in neural tissues and glioma\"\n        },\n        {\n          \"source_id\": \"68\",\n          \"notes\": \"Defines BBB and neural tissue organization through cell adhesion molecules\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"CDH2\",\n        \"CTNNA3\",\n        \"PCDH9\",\n        \"CADM1\",\n        \"NTM\",\n        \"NLGN4X\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"CTNNB1\",\n          \"CDH1\",\n          \"NCAM1\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"68\",\n            \"notes\": \"Beta-catenin and E-cadherin are critical components of adherens junctions often dysregulated in epithelial cancers\"\n          },\n          {\n            \"source_id\": \"36\",\n            \"notes\": \"NCAM1 represents another key neural CAM often altered in glioma\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Cytoskeletal Reorganization and Enhanced Motility\",\n      \"description\": \"Coordinated dysregulation of actin-myosin machinery, focal adhesion components, and planar polarity effectors that reorient the cytoskeleton from a static, neuron-support configuration toward a dynamic, migratory phenotype. This program encompasses myosin motor proteins, kinase regulators of actin dynamics, and adhesion site remodeling components.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Actin polymerization and actomyosin contraction\",\n          \"citations\": [\n            {\n              \"source_id\": \"6\",\n              \"notes\": \"PRKD1 regulates actin bundling and contractility through phosphorylation of MARCKS and related proteins\"\n            },\n            {\n              \"source_id\": \"27\",\n              \"notes\": \"SUCLG2 knockdown affects mitochondrial oxidative phosphorylation, which couples to actin dynamics\"\n            }\n          ],\n          \"genes\": [\n            \"PRKD1\",\n            \"PRICKLE2\",\n            \"DTNA\"\n          ]\n        },\n        {\n          \"name\": \"Myosin motor-mediated force generation and trafficking\",\n          \"citations\": [\n            {\n              \"source_id\": \"27\",\n              \"notes\": \"Motor protein dysfunction affects cellular transport and energy metabolism\"\n            }\n          ],\n          \"genes\": [\n            \"MYO5B\",\n            \"MYO1E\",\n            \"MYO16\",\n            \"MYO3B\"\n          ]\n        },\n        {\n          \"name\": \"Focal adhesion remodeling and dynamics\",\n          \"citations\": [\n            {\n              \"source_id\": \"68\",\n              \"notes\": \"PARD3 organizes cell polarity complexes and adhesion sites critical for cell migration control\"\n            }\n          ],\n          \"genes\": [\n            \"PARD3\",\n            \"PARD3B\",\n            \"PDLIM5\"\n          ]\n        },\n        {\n          \"name\": \"Planar cell polarity and directional migration\",\n          \"citations\": [\n            {\n              \"source_id\": \"68\",\n              \"notes\": \"PRICKLE2 participates in planar polarity signaling affecting cell orientation and migration\"\n            }\n          ],\n          \"genes\": [\n            \"PRICKLE2\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Actin filaments and myosin motor complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"27\",\n              \"notes\": \"Mitochondrial metabolism couples to actin dynamics through ATP availability for myosin ATPase\"\n            }\n          ],\n          \"genes\": [\n            \"MYO5B\",\n            \"MYO1E\",\n            \"MYO16\",\n            \"MYO3B\",\n            \"PRKD1\"\n          ]\n        },\n        {\n          \"name\": \"Focal adhesions\",\n          \"citations\": [\n            {\n              \"source_id\": \"68\",\n              \"notes\": \"PAR polarity complexes organize focal adhesions at cell-ECM interface\"\n            }\n          ],\n          \"genes\": [\n            \"PARD3\",\n            \"PARD3B\",\n            \"PDLIM5\"\n          ]\n        },\n        {\n          \"name\": \"Planar polarity complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"68\",\n              \"notes\": \"PRICKLE proteins participate in non-canonical Wnt signaling and cell orientation\"\n            }\n          ],\n          \"genes\": [\n            \"PRICKLE2\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced cell migration speed and directional persistence\",\n        \"Increased invasiveness through 3D ECM and along white matter tracts\",\n        \"Altered morphodynamics enabling tumor cells to navigate narrow tissue spaces\",\n        \"Increased actomyosin contractility driving mechanical force generation\",\n        \"Disrupted contact inhibition through impaired focal adhesion signaling\"\n      ],\n      \"evidence_summary\": \"The extensive representation of myosin isoforms, actin regulators, and focal adhesion components indicates coordinated reorientation of the cytoskeleton in astrocytoma. Normal astrocytes maintain relatively stationary morphology optimized for neuronal support; transformation requires dynamic cytoskeletal reorganization. The presence of multiple myosin isoforms (MYO5B for trafficking, MYO1E for membrane dynamics, MYO16 for actin organization, MYO3B for specialized functions) suggests both enhanced force generation and altered vesicular trafficking. Combined with focal adhesion remodeling genes, this program predicts a fundamental shift toward migratory phenotype characteristic of infiltrative tumors.\",\n      \"significance_score\": 0.79,\n      \"citations\": [\n        {\n          \"source_id\": \"6\",\n          \"notes\": \"Demonstrates PRKD1 role in actin regulation and cell migration\"\n        },\n        {\n          \"source_id\": \"27\",\n          \"notes\": \"Links metabolic state to cytoskeletal dynamics through energy coupling\"\n        },\n        {\n          \"source_id\": \"68\",\n          \"notes\": \"Comprehensive analysis of cell polarity and migration control in 3D tissue models\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"PRKD1\",\n        \"MYO5B\",\n        \"MYO1E\",\n        \"MYO16\",\n        \"MYO3B\",\n        \"PARD3\",\n        \"PARD3B\",\n        \"PDLIM5\",\n        \"PRICKLE2\",\n        \"DTNA\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"RHOA\",\n          \"RAC1\",\n          \"CDC42\",\n          \"ROCK1\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"28\",\n            \"notes\": \"ILK silencing inhibits glioblastoma migration through ROCK1 and Fascin-1 downregulation, indicating Rho GTPase pathway involvement\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Extracellular Matrix Remodeling\",\n      \"description\": \"Dysregulation of matrix proteases, ECM protein synthesis, and ECM-modifying enzymes that collectively enable transformation of a neuron-supportive ECM into a tumor-permissive niche. This program involves matrix metalloproteinases, heparan sulfate modifiers, and structural ECM components that construct pro-tumoral matrix architecture.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Extracellular matrix protein degradation\",\n          \"citations\": [\n            {\n              \"source_id\": \"26\",\n              \"notes\": \"GLUL drives angiogenesis and vascular niche formation through PI3K/AKT signaling involving ECM remodeling\"\n            },\n            {\n              \"source_id\": \"27\",\n              \"notes\": \"SUCLG2 knockdown affects proteasomal degradation and cellular proteostasis related to ECM proteins\"\n            },\n            {\n              \"source_id\": \"45\",\n              \"notes\": \"Spatial transcriptomics reveal differential ECM expression in GBM tumor regions\"\n            }\n          ],\n          \"genes\": [\n            \"ADAMTS6\",\n            \"ADAMTS14\",\n            \"ADAMTS9-AS2\"\n          ]\n        },\n        {\n          \"name\": \"Heparan sulfate biosynthesis and modification\",\n          \"citations\": [\n            {\n              \"source_id\": \"45\",\n              \"notes\": \"ECM components including heparan sulfate proteoglycans regulate GBM progression\"\n            }\n          ],\n          \"genes\": [\n            \"HS3ST3B1\",\n            \"SULF1\",\n            \"NDST3\"\n          ]\n        },\n        {\n          \"name\": \"Structural ECM protein synthesis and organization\",\n          \"citations\": [\n            {\n              \"source_id\": \"45\",\n              \"notes\": \"Collagen and other structural ECM proteins are differentially expressed in GBM tumor regions\"\n            }\n          ],\n          \"genes\": [\n            \"COL8A1\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Matrix metalloproteinase complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"27\",\n              \"notes\": \"Matrix metalloproteinases regulate proteolytic degradation of ECM and cytoplasmic proteins\"\n            }\n          ],\n          \"genes\": [\n            \"ADAMTS6\",\n            \"ADAMTS14\",\n            \"ADAMTS9-AS2\"\n          ]\n        },\n        {\n          \"name\": \"Heparan sulfate proteoglycans\",\n          \"citations\": [\n            {\n              \"source_id\": \"45\",\n              \"notes\": \"Heparan sulfate modifications regulate growth factor signaling and cell-ECM interactions\"\n            }\n          ],\n          \"genes\": [\n            \"HS3ST3B1\",\n            \"SULF1\",\n            \"NDST3\"\n          ]\n        },\n        {\n          \"name\": \"Basement membrane and stromal collagens\",\n          \"citations\": [\n            {\n              \"source_id\": \"45\",\n              \"notes\": \"Collagen VIII and other collagens form structural ECM framework\"\n            }\n          ],\n          \"genes\": [\n            \"COL8A1\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced degradation of inhibitory ECM components constraining tumor growth\",\n        \"Construction of pro-tumoral matrix architecture supporting angiogenesis and invasion\",\n        \"Increased growth factor bioavailability through heparan sulfate modification\",\n        \"Altered ECM-integrin signaling promoting tumor cell proliferation and migration\",\n        \"Remodeled basement membranes facilitating vascular invasion and perivascular niche formation\"\n      ],\n      \"evidence_summary\": \"Glioblastoma progression critically depends on ECM remodeling, with both enhanced protease activity and altered ECM composition characterizing tumors (sources 26, 27, 45). The input gene list captures multiple layers of this remodeling: ADAMTS proteases for enzymatic degradation, heparan sulfate modifiers (HS3ST3B1, SULF1) for altered growth factor signaling capacity, and structural collagen genes for ECM construction. The presence of both proteases (ADAMTS) and their counterregulatory genes (SULF1 against HS3ST) suggests dynamic, carefully regulated ECM remodeling rather than simple dysregulation. Dysregulation would create permissive microenvironment supporting tumor cell proliferation, migration, and angiogenesis while reducing normal ECM constraints.\",\n      \"significance_score\": 0.81,\n      \"citations\": [\n        {\n          \"source_id\": \"26\",\n          \"notes\": \"Demonstrates GLUL's role in glioma angiogenesis through PI3K/AKT-dependent ECM remodeling\"\n        },\n        {\n          \"source_id\": \"27\",\n          \"notes\": \"Shows proteolytic and metabolic coupling in glioblastoma through SUCLG2\"\n        },\n        {\n          \"source_id\": \"45\",\n          \"notes\": \"Single-cell spatial transcriptomics reveal ECM expression patterns in GBM tumor microenvironment\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"ADAMTS6\",\n        \"ADAMTS14\",\n        \"ADAMTS9-AS2\",\n        \"HS3ST3B1\",\n        \"SULF1\",\n        \"COL8A1\",\n        \"NDST3\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"MMP2\",\n          \"MMP9\",\n          \"MMP14\",\n          \"TIMP3\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"12\",\n            \"notes\": \"TIMP3 modulates ECM remodeling during development and disease\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Transcriptional Reprogramming\",\n      \"description\": \"Dysregulation of transcription factors and regulatory non-coding RNAs that redefine the astrocytoma transcriptome from a differentiation-dominated state toward one supporting stemness, proliferation, and tumor-promoting properties. This program involves transcription factors controlling neural development (GLI3, ETV1, ETV6), regulatory non-coding RNAs (SOX2-OT, lncRNAs), and chromatin remodeling factors.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Transcriptional regulation of neural development and cell fate\",\n          \"citations\": [\n            {\n              \"source_id\": \"25\",\n              \"notes\": \"GLI1 and related factors regulate glioma cell differentiation and tumor progression\"\n            },\n            {\n              \"source_id\": \"40\",\n              \"notes\": \"SOX2 and related transcription factors control stem cell identity and neural progenitor specification\"\n            }\n          ],\n          \"genes\": [\n            \"GLI3\",\n            \"ETV1\",\n            \"ETV6\",\n            \"RFX4\",\n            \"SOX2-OT\"\n          ]\n        },\n        {\n          \"name\": \"Chromatin remodeling and histone modification\",\n          \"citations\": [\n            {\n              \"source_id\": \"23\",\n              \"notes\": \"SETBP1 regulates histone deacetylase activity and chromatin accessibility\"\n            },\n            {\n              \"source_id\": \"40\",\n              \"notes\": \"ARID5B and PRDM16 participate in chromatin remodeling affecting cell differentiation\"\n            }\n          ],\n          \"genes\": [\n            \"SETBP1\",\n            \"ARID5B\",\n            \"PRDM16\"\n          ]\n        },\n        {\n          \"name\": \"Post-transcriptional and epigenetic regulation via lncRNAs\",\n          \"citations\": [\n            {\n              \"source_id\": \"40\",\n              \"notes\": \"SOX2-OT and related long non-coding RNAs regulate expression of associated protein-coding genes\"\n            },\n            {\n              \"source_id\": \"46\",\n              \"notes\": \"Alternative splicing and lncRNA-mediated regulation influence neural development and disease\"\n            }\n          ],\n          \"genes\": [\n            \"SOX2-OT\",\n            \"LINC01993\",\n            \"LINC00511\",\n            \"LINC01122\",\n            \"NR2F2-AS1\",\n            \"SOCS2-AS1\",\n            \"SCN1A-AS1\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Transcription factor complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"25\",\n              \"notes\": \"GLI family transcription factors form regulatory complexes controlling gene expression\"\n            },\n            {\n              \"source_id\": \"40\",\n              \"notes\": \"Multiple transcription factors coordinate neural differentiation programs\"\n            }\n          ],\n          \"genes\": [\n            \"GLI3\",\n            \"ETV1\",\n            \"ETV6\",\n            \"RFX4\"\n          ]\n        },\n        {\n          \"name\": \"Chromatin remodeling complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"40\",\n              \"notes\": \"ARID5B and related factors participate in SWI/SNF-like chromatin remodeling complexes\"\n            }\n          ],\n          \"genes\": [\n            \"ARID5B\",\n            \"PRDM16\"\n          ]\n        },\n        {\n          \"name\": \"Regulatory non-coding RNA molecules\",\n          \"citations\": [\n            {\n              \"source_id\": \"40\",\n              \"notes\": \"Long non-coding RNAs regulate gene expression through multiple mechanisms\"\n            },\n            {\n              \"source_id\": \"46\",\n              \"notes\": \"lncRNAs participate in alternative splicing and chromatin regulation\"\n            }\n          ],\n          \"genes\": [\n            \"SOX2-OT\",\n            \"LINC01993\",\n            \"LINC00511\",\n            \"LINC01122\",\n            \"NR2F2-AS1\",\n            \"SOCS2-AS1\",\n            \"SCN1A-AS1\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Loss of astrocyte-specific differentiation gene expression (GFAP, ALDH1A1, etc.)\",\n        \"Activation of neural progenitor and stemness-associated genes\",\n        \"Enhanced proliferation through altered cell cycle checkpoint regulation\",\n        \"Altered chromatin accessibility at oncogenic and tumor-suppressor loci\",\n        \"Dysregulated expression of metabolic enzymes supporting malignant phenotype\",\n        \"Maintained or increased expression of stemness factors preventing terminal differentiation\"\n      ],\n      \"evidence_summary\": \"The comprehensive representation of transcription factors and regulatory RNAs indicates fundamental reprogramming of the astrocytoma transcriptome. GLI3 reactivation would dysregulate hedgehog pathway targets (source 25); ETV family factors control developmental processes often dysregulated in cancer; SOX2-associated regulatory networks maintain stemness incompatible with normal astrocyte differentiation (source 40). The presence of multiple lncRNAs suggests layered transcriptional control through both classical transcription factors and post-transcriptional mechanisms (sources 40, 46). Collectively, these factors would repress differentiation-associated astrocyte genes while activating oncogenic and stemness-associated programs. This transcriptional remodeling represents a fundamental reprogramming from differentiated astrocyte identity toward a progenitor-like, tumor-promoting state.\",\n      \"significance_score\": 0.84,\n      \"citations\": [\n        {\n          \"source_id\": \"23\",\n          \"notes\": \"SETBP1 drives chromatin remodeling in myelodysplastic syndrome through altered histone deacetylase activity\"\n        },\n        {\n          \"source_id\": \"25\",\n          \"notes\": \"GLI1 participates in hypoxia-induced glioma progression\"\n        },\n        {\n          \"source_id\": \"40\",\n          \"notes\": \"Transcriptome analysis reveals SOX2 expression and stemness-associated gene programs\"\n        },\n        {\n          \"source_id\": \"46\",\n          \"notes\": \"Alternative splicing and lncRNA regulation affect neural development\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"GLI3\",\n        \"ETV1\",\n        \"ETV6\",\n        \"RFX4\",\n        \"SETBP1\",\n        \"ARID5B\",\n        \"PRDM16\",\n        \"SOX2-OT\",\n        \"LINC01993\",\n        \"LINC00511\",\n        \"LINC01122\",\n        \"NR2F2-AS1\",\n        \"SOCS2-AS1\",\n        \"SCN1A-AS1\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"SOX2\",\n          \"OLIG2\",\n          \"NF1\",\n          \"TP53\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"40\",\n            \"notes\": \"SOX2 encodes critical transcription factor for stem cell and neural progenitor maintenance\"\n          },\n          {\n            \"source_id\": \"10\",\n            \"notes\": \"TP53 tumor suppressor frequently dysregulated in gliomas\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Metabolic Reprogramming\",\n      \"description\": \"Dysregulation of metabolic enzymes supporting lipid synthesis, fatty acid oxidation, and nucleotide metabolism that collectively support the biosynthetic demands of rapidly proliferating astrocytoma cells. This program reflects transformation from a metabolic state optimized for neuronal support toward one maximizing biosynthetic capacity for rapid cell division.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Fatty acid and lipid biosynthesis\",\n          \"citations\": [\n            {\n              \"source_id\": \"27\",\n              \"notes\": \"SUCLG2 couples mitochondrial metabolism to lipid synthesis and cell proliferation\"\n            },\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"Mallotumide A targets lipid metabolism enzymes ACC1 and FASN in cancer cells\"\n            }\n          ],\n          \"genes\": [\n            \"ACSBG1\",\n            \"ACSS3\",\n            \"PLS3\",\n            \"PLPP4\",\n            \"PLCH1\",\n            \"PLCG2\",\n            \"PLCE1\",\n            \"PLCB4\"\n          ]\n        },\n        {\n          \"name\": \"Mitochondrial oxidative phosphorylation and energy metabolism\",\n          \"citations\": [\n            {\n              \"source_id\": \"27\",\n              \"notes\": \"SUCLG2 regulates mitochondrial oxidative phosphorylation critical for proliferation\"\n            },\n            {\n              \"source_id\": \"30\",\n              \"notes\": \"Caveolin-2 expressing nerves shift cancer cell metabolism toward oxidative phosphorylation\"\n            }\n          ],\n          \"genes\": [\n            \"MT-CYB\",\n            \"MT-CO2\",\n            \"MT-CO3\",\n            \"MCUB\"\n          ]\n        },\n        {\n          \"name\": \"Nucleotide and polyamine synthesis\",\n          \"citations\": [\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"Cancer cells activate metabolic pathways supporting nucleotide synthesis for DNA replication\"\n            }\n          ],\n          \"genes\": [\n            \"PGM2L1\",\n            \"PGM5\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Fatty acid synthesis complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"ACC and FASN enzymes catalyze de novo lipogenesis essential for rapid cell division\"\n            }\n          ],\n          \"genes\": [\n            \"ACSBG1\",\n            \"ACSS3\"\n          ]\n        },\n        {\n          \"name\": \"Phospholipid and lipid signaling molecules\",\n          \"citations\": [\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"Phospholipids and signaling lipids participate in cancer cell proliferation and survival\"\n            }\n          ],\n          \"genes\": [\n            \"PLS3\",\n            \"PLPP4\",\n            \"PLCH1\",\n            \"PLCG2\",\n            \"PLCE1\",\n            \"PLCB4\"\n          ]\n        },\n        {\n          \"name\": \"Mitochondrial complexes and energy production\",\n          \"citations\": [\n            {\n              \"source_id\": \"27\",\n              \"notes\": \"Mitochondrial electron transport chain components including cytochrome b and oxidases\"\n            }\n          ],\n          \"genes\": [\n            \"MT-CYB\",\n            \"MT-CO2\",\n            \"MT-CO3\",\n            \"MCUB\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced ATP production supporting rapid cell division\",\n        \"Increased lipid synthesis for membranogenesis during tumor growth\",\n        \"Altered metabolic competition with adjacent neurons\",\n        \"Potential Warburg effect-like glycolytic switching supporting tumor progression\",\n        \"Enhanced nucleotide synthesis enabling rapid DNA replication\",\n        \"Altered oxidative stress biology through changes in mitochondrial metabolism\"\n      ],\n      \"evidence_summary\": \"Metabolic reprogramming is a hallmark of glioblastoma progression, with tumor cells exhibiting altered oxidative and glycolytic metabolism (sources 27, 30). The input gene list captures components of fatty acid synthesis (ACSBG1, ACSS3), lipid signaling (multiple PLC isoforms), and mitochondrial metabolism (MT-encoded genes). Normal astrocytes prioritize oxidative metabolism supporting neuronal energy demands; transformed astrocytes would reprogram toward biosynthetic metabolism supporting rapid cell division. The presence of multiple lipid metabolism genes indicates coordinated dysregulation across lipid synthesis and signaling pathways. These changes would provide the biosynthetic capacity required for tumor growth while potentially contributing to metabolic competition with adjacent neurons.\",\n      \"significance_score\": 0.77,\n      \"citations\": [\n        {\n          \"source_id\": \"27\",\n          \"notes\": \"SUCLG2 couples mitochondrial metabolism to cancer cell proliferation and metabolic remodeling\"\n        },\n        {\n          \"source_id\": \"30\",\n          \"notes\": \"Tumor-associated nerves promote metabolic reprogramming toward mitochondrial oxidative phosphorylation\"\n        },\n        {\n          \"source_id\": \"31\",\n          \"notes\": \"Mallotumide A targets cancer cell metabolic enzymes including those of lipid synthesis\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"ACSBG1\",\n        \"ACSS3\",\n        \"PLS3\",\n        \"PLPP4\",\n        \"PLCH1\",\n        \"PLCG2\",\n        \"PLCE1\",\n        \"PLCB4\",\n        \"MT-CYB\",\n        \"MT-CO2\",\n        \"MT-CO3\",\n        \"MCUB\",\n        \"PGM2L1\",\n        \"PGM5\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"PKM2\",\n          \"LDHA\",\n          \"HK2\",\n          \"GLUL\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"26\",\n            \"notes\": \"GLUL participates in glutamate and energy metabolism in transformed astrocytes\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Ion Channel and Electrophysiological Remodeling\",\n      \"description\": \"Dysregulation of voltage-gated ion channels that alters the electrophysiological properties of transformed astrocytes from relatively non-excitable cells toward more excitable phenotypes capable of active electrical signaling. This program encompasses sodium channels, potassium channels, and associated regulatory proteins.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Voltage-gated sodium channel function and action potential generation\",\n          \"citations\": [\n            {\n              \"source_id\": \"5\",\n              \"notes\": \"SCN1A encodes Nav1.1 sodium channel critical for neuronal excitability and action potentials\"\n            }\n          ],\n          \"genes\": [\n            \"SCN1A\",\n            \"SCN1A-AS1\"\n          ]\n        },\n        {\n          \"name\": \"Voltage-gated potassium channel function and excitability control\",\n          \"citations\": [\n            {\n              \"source_id\": \"5\",\n              \"notes\": \"KCND3 encodes Kv4.3 potassium channel regulating intrinsic excitability and repolarization\"\n            }\n          ],\n          \"genes\": [\n            \"KCND3\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Sodium channel complex\",\n          \"citations\": [\n            {\n              \"source_id\": \"5\",\n              \"notes\": \"SCN1A forms functional sodium channel necessary for action potential initiation\"\n            }\n          ],\n          \"genes\": [\n            \"SCN1A\"\n          ]\n        },\n        {\n          \"name\": \"Potassium channel complex\",\n          \"citations\": [\n            {\n              \"source_id\": \"5\",\n              \"notes\": \"KCND3 forms rapidly inactivating A-type potassium channel regulating membrane potential\"\n            }\n          ],\n          \"genes\": [\n            \"KCND3\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced intrinsic excitability of transformed astrocytes\",\n        \"Potential generation of ectopic electrical activity influencing peritumoral neural circuits\",\n        \"Altered membrane potential dynamics affecting ion-dependent signaling\",\n        \"Increased responsiveness to synaptic inputs from adjacent neurons\",\n        \"Potential contribution to tumor-associated seizures through altered network-level excitability\"\n      ],\n      \"evidence_summary\": \"While direct evidence for ion channel dysregulation driving astrocytoma progression is less extensive than for other programs, the presence of SCN1A and KCND3 in the input gene list suggests altered electrophysiology is characteristic of astrocytic transformation. Normal mature astrocytes are largely non-excitable; acquisition of sodium channel expression would render them capable of active electrical signaling. The altered electrical properties could influence peritumoral neural circuits through direct synaptic transmission and network-level effects (source 17). Ion channel remodeling represents an emerging but potentially important aspect of tumor-neuron crosstalk.\",\n      \"significance_score\": 0.65,\n      \"citations\": [\n        {\n          \"source_id\": \"5\",\n          \"notes\": \"Comprehensive analysis of ion channels in neural development and function\"\n        },\n        {\n          \"source_id\": \"17\",\n          \"notes\": \"Aberrant neural activity in peritumoral cortex contributes to tumor-associated seizures\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"SCN1A\",\n        \"KCND3\",\n        \"SCN1A-AS1\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"CACNA1C\",\n          \"GRIN1\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"5\",\n            \"notes\": \"Calcium channels and NMDA receptors participate in neuronal excitability and calcium signaling\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"DNA Damage Response and Genomic Instability\",\n      \"description\": \"Dysregulation of DNA repair machinery and cell cycle checkpoint control that permits accumulation of additional genetic mutations while simultaneously maintaining proliferative capacity. This program reflects how astrocytomas acquire multiple secondary mutations beyond initial transformation events, driving tumor heterogeneity and evolution.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Double-strand break detection and repair\",\n          \"citations\": [\n            {\n              \"source_id\": \"35\",\n              \"notes\": \"PRKDC encodes DNA-PKcs critical for non-homologous end joining DNA repair\"\n            },\n            {\n              \"source_id\": \"65\",\n              \"notes\": \"DNA-PK participates in DNA damage signaling and genomic instability\"\n            }\n          ],\n          \"genes\": [\n            \"PRKDC\"\n          ]\n        },\n        {\n          \"name\": \"Homologous recombination and DNA repair\",\n          \"citations\": [\n            {\n              \"source_id\": \"61\",\n              \"notes\": \"BRCA2 participates in homologous recombination-mediated DNA repair\"\n            }\n          ],\n          \"genes\": [\n            \"BRCA2\"\n          ]\n        },\n        {\n          \"name\": \"Cell cycle progression and mitotic checkpoint\",\n          \"citations\": [\n            {\n              \"source_id\": \"64\",\n              \"notes\": \"NEK6 regulates cell cycle progression and mitotic fidelity\"\n            }\n          ],\n          \"genes\": [\n            \"NEK6\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"DNA damage response complex\",\n          \"citations\": [\n            {\n              \"source_id\": \"35\",\n              \"notes\": \"DNA-PKcs functions in multi-protein complexes detecting and repairing double-strand breaks\"\n            }\n          ],\n          \"genes\": [\n            \"PRKDC\"\n          ]\n        },\n        {\n          \"name\": \"Homologous recombination machinery\",\n          \"citations\": [\n            {\n              \"source_id\": \"61\",\n              \"notes\": \"BRCA2 associates with RAD51 and other recombination proteins\"\n            }\n          ],\n          \"genes\": [\n            \"BRCA2\"\n          ]\n        },\n        {\n          \"name\": \"Cell cycle checkpoint complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"64\",\n              \"notes\": \"NEK kinases participate in centrosome maturation and cell cycle control\"\n            }\n          ],\n          \"genes\": [\n            \"NEK6\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Impaired DNA damage detection or repair enabling mutation accumulation\",\n        \"Enhanced chromosomal instability through compromised checkpoint control\",\n        \"Acquisition of secondary oncogenic mutations during tumor evolution\",\n        \"Potential resistance to DNA-damaging chemotherapy or radiotherapy\",\n        \"Increased tumor heterogeneity through enhanced genetic diversity\"\n      ],\n      \"evidence_summary\": \"Astrocytomas and glioblastomas typically harbor multiple mutations beyond initial transformation events, reflecting genomic instability (source 47, 59). The presence of DNA repair (PRKDC, BRCA2) and cell cycle (NEK6) genes indicates dysregulation of genomic stability control. Altered PRKDC expression could impair NHEJ repair, enabling accumulation of DNA damage. This dysregulation would permit secondary mutations driving tumor evolution and heterogeneity while maintaining sufficient proliferative capacity for continued growth. Genomic instability represents a double-edged sword: it promotes tumor heterogeneity and adaptation but also potentially creates vulnerabilities to DNA-targeting therapies.\",\n      \"significance_score\": 0.68,\n      \"citations\": [\n        {\n          \"source_id\": \"35\",\n          \"notes\": \"DNA-PKcs role in DNA damage signaling and non-homologous end joining\"\n        },\n        {\n          \"source_id\": \"47\",\n          \"notes\": \"Multi-hit genetic alterations characterize high-grade gliomas\"\n        },\n        {\n          \"source_id\": \"61\",\n          \"notes\": \"BRCA2 participates in homologous recombination DNA repair\"\n        },\n        {\n          \"source_id\": \"64\",\n          \"notes\": \"NEK6 participates in cell cycle regulation and mitotic progression\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"PRKDC\",\n        \"BRCA2\",\n        \"NEK6\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"ATM\",\n          \"TP53\",\n          \"CDKN1A\",\n          \"PTEN\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"10\",\n            \"notes\": \"TP53 tumor suppressor frequently dysregulated in gliomas including through R175H hotspot mutation\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Signaling Pathway Integration and Growth Promotion\",\n      \"description\": \"Dysregulation of phospholipase C, Rho GTPase, and receptor tyrosine kinase signaling pathways that collectively amplify growth and survival signals while reducing growth inhibitory inputs. This program encompasses multiple signaling modalities that converge on central nodes (PI3K-AKT, MAPK) driving tumor progression.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Phospholipase C-mediated calcium and PKC signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"Phospholipase C enzymes cleave phosphatidylinositol bisphosphate generating IP3 and DAG\"\n            }\n          ],\n          \"genes\": [\n            \"PLCE1\",\n            \"PLCB4\",\n            \"PLCH1\",\n            \"PLCG2\"\n          ]\n        },\n        {\n          \"name\": \"PI3K-AKT-mTOR pathway amplification\",\n          \"citations\": [\n            {\n              \"source_id\": \"26\",\n              \"notes\": \"GLUL-driven CAF activation occurs through PI3K/AKT signaling central to glioma progression\"\n            },\n            {\n              \"source_id\": \"29\",\n              \"notes\": \"Pericytes orchestrate tumor-restraining microenvironment partially through PI3K signaling\"\n            }\n          ],\n          \"genes\": [\n            \"PREX2\",\n            \"PRKD1\",\n            \"PRKCA\"\n          ]\n        },\n        {\n          \"name\": \"Receptor tyrosine kinase signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"47\",\n              \"notes\": \"NTRK2 fusion genes promote oncogenic signaling in gliomas\"\n            },\n            {\n              \"source_id\": \"30\",\n              \"notes\": \"Caveolin-2 modulates neuronal signaling affecting cancer cell phenotype\"\n            }\n          ],\n          \"genes\": [\n            \"NTRK3\",\n            \"PTN\",\n            \"PDGFC\",\n            \"PDGFRA\"\n          ]\n        },\n        {\n          \"name\": \"Hedgehog and Wnt pathway signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"25\",\n              \"notes\": \"GLI1 participates in hedgehog pathway-driven glioma progression\"\n            },\n            {\n              \"source_id\": \"51\",\n              \"notes\": \"RGS20 inhibition enhances WNT/β-catenin signaling in glioma stem cells\"\n            }\n          ],\n          \"genes\": [\n            \"GLI3\",\n            \"PTCH2\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Phospholipase C enzyme complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"Multiple PLC isoforms generate diverse lipid signaling molecules\"\n            }\n          ],\n          \"genes\": [\n            \"PLCE1\",\n            \"PLCB4\",\n            \"PLCH1\",\n            \"PLCG2\"\n          ]\n        },\n        {\n          \"name\": \"PI3K-AKT-mTOR signaling cascade\",\n          \"citations\": [\n            {\n              \"source_id\": \"26\",\n              \"notes\": \"PI3K/AKT pathway central hub for integrating multiple growth signals in glioma\"\n            }\n          ],\n          \"genes\": [\n            \"PREX2\",\n            \"PRKD1\",\n            \"PRKCA\"\n          ]\n        },\n        {\n          \"name\": \"Growth factor receptor complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"47\",\n              \"notes\": \"NTRK2 fusion promotes constitutive tyrosine kinase signaling\"\n            }\n          ],\n          \"genes\": [\n            \"NTRK3\",\n            \"PDGFRA\",\n            \"PTN\",\n            \"PDGFC\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced calcium signaling supporting proliferation and migration\",\n        \"Amplified PI3K-AKT signaling promoting cell survival and growth\",\n        \"Increased responsiveness to growth factors through altered receptor expression\",\n        \"Activated hedgehog pathway supporting stemness and tumor progression\",\n        \"Enhanced Wnt signaling maintaining stem cell properties\",\n        \"Increased secretion of growth factors (PTN, PDGFC) promoting autocrine and paracrine signaling\"\n      ],\n      \"evidence_summary\": \"Multiple signaling pathways are dysregulated in glioblastoma, with PI3K-AKT representing a central hub integrating diverse inputs (sources 26, 29). The input gene list captures components of phospholipase C signaling (multiple PLC isoforms), downstream effectors (PREX2, PRKD1, PRKCA), and upstream receptor engagement (NTRK3, PDGFRA, PTN, PDGFC). The presence of both secreted ligands (PTN, PDGFC) and their cognate receptors or downstream effectors suggests both autocrine and paracrine signaling amplification. Dysregulation across multiple pathway modalities (PLC, PI3K-AKT, hedgehog, Wnt) suggests redundant signaling networks that provide robustness and compensatory capacity. Collectively, these changes would create a hyperresponsive state to growth-promoting signals while reducing response to growth-inhibitory inputs.\",\n      \"significance_score\": 0.80,\n      \"citations\": [\n        {\n          \"source_id\": \"25\",\n          \"notes\": \"GLI1 participates in hypoxia-induced glioma progression through hedgehog signaling\"\n        },\n        {\n          \"source_id\": \"26\",\n          \"notes\": \"GLUL-driven CAF activation through PI3K/AKT signaling promotes glioma angiogenesis\"\n        },\n        {\n          \"source_id\": \"29\",\n          \"notes\": \"Pericytes regulate tumor microenvironment through multiple signaling pathways\"\n        },\n        {\n          \"source_id\": \"30\",\n          \"notes\": \"Caveolin-2 modulates nerve-mediated effects on cancer cell metabolism and stemness\"\n        },\n        {\n          \"source_id\": \"47\",\n          \"notes\": \"NTRK2 fusion genes in gliomas drive oncogenic signaling\"\n        },\n        {\n          \"source_id\": \"51\",\n          \"notes\": \"RGS20 suppression activates WNT/β-catenin signaling in glioma stem cells\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"PLCE1\",\n        \"PLCB4\",\n        \"PLCH1\",\n        \"PLCG2\",\n        \"PREX2\",\n        \"PRKD1\",\n        \"PRKCA\",\n        \"NTRK3\",\n        \"PTN\",\n        \"PDGFC\",\n        \"PDGFRA\",\n        \"GLI3\",\n        \"PTCH2\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"PIK3CA\",\n          \"AKT1\",\n          \"MTOR\",\n          \"PTEN\",\n          \"EGFR\",\n          \"PDGFRA\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"11\",\n            \"notes\": \"AKT1 is downstream target of PI3K in controlling angiogenesis and tumor growth\"\n          },\n          {\n            \"source_id\": \"33\",\n            \"notes\": \"SHH and PI3K pathways synergize in PTEN-deficient glioblastomas\"\n          }\n        ]\n      }\n    }\n  ],\n  \"method\": {\n    \"clustering_basis\": [\n      \"Pathway database analysis (hedgehog, Wnt, PI3K-AKT)\",\n      \"Functional annotation of gene products based on literature\",\n      \"Co-expression patterns inferred from cancer biology studies\",\n      \"Biological process clustering (adhesion, motility, metabolism, etc.)\",\n      \"Cell type specificity considering astrocyte physiology and transformation\"\n    ],\n    \"notes\": \"Gene programs identified through systematic analysis of input gene list against current literature on normal astrocyte physiology, astrocytoma biology, and glioblastoma progression. Programs represent functionally coherent clusters of genes acting together in discrete biological processes or cellular systems. Eight major programs identified spanning synaptic interface, cell adhesion, cytoskeletal dynamics, ECM remodeling, transcriptional control, metabolism, electrophysiology, and genomic stability. Significance scores reflect both supporting literature evidence and completeness of pathway representation in input gene list.\"\n  },\n  \"version\": \"1.0\"\n}\n```",
    "citations": [
      "https://www.ncbi.nlm.nih.gov/gene/7422",
      "https://www.ncbi.nlm.nih.gov/gene/3265",
      "https://www.ncbi.nlm.nih.gov/gene/4916",
      "https://www.nature.com/articles/s41467-025-66504-2",
      "https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=2902",
      "https://www.nature.com/articles/s42003-025-09169-3",
      "https://www.ncbi.nlm.nih.gov/clinvar/variation/12355/",
      "https://www.ncbi.nlm.nih.gov/gene/19211",
      "https://www.nature.com/articles/s42003-025-09138-w",
      "https://www.ncbi.nlm.nih.gov/clinvar/variation/VCV000012374",
      "https://www.ncbi.nlm.nih.gov/gene/207",
      "https://www.ncbi.nlm.nih.gov/gene/7078",
      "https://www.ncbi.nlm.nih.gov/gene/4314",
      "https://www.ncbi.nlm.nih.gov/gene/3383",
      "https://www.ncbi.nlm.nih.gov/gene/20674",
      "https://www.nature.com/articles/s41467-025-66226-5",
      "https://www.ncbi.nlm.nih.gov/gene/10419",
      "https://www.ncbi.nlm.nih.gov/gene/7015",
      "https://www.ncbi.nlm.nih.gov/gene/12151",
      "https://www.ncbi.nlm.nih.gov/gene/29126",
      "https://www.ncbi.nlm.nih.gov/gene/5725",
      "https://www.nature.com/articles/s41467-025-65806-9",
      "https://www.ncbi.nlm.nih.gov/gene/26040",
      "https://www.ncbi.nlm.nih.gov/gene/2735",
      "https://pubmed.ncbi.nlm.nih.gov/41355614/",
      "https://www.nature.com/articles/s41420-025-02856-4",
      "https://www.ncbi.nlm.nih.gov/gene/3611",
      "https://www.nature.com/articles/s41467-025-66985-1",
      "https://www.nature.com/articles/s41467-025-66914-2",
      "https://www.nature.com/articles/s41598-025-24547-x",
      "https://www.ncbi.nlm.nih.gov/gene/6506",
      "https://www.ncbi.nlm.nih.gov/gene/6469",
      "https://www.ncbi.nlm.nih.gov/gene/5564",
      "https://www.ncbi.nlm.nih.gov/gene/5591",
      "https://www.nature.com/articles/s41467-025-66521-1",
      "https://www.ncbi.nlm.nih.gov/gene/5292",
      "https://www.ncbi.nlm.nih.gov/gene/140885",
      "https://www.ncbi.nlm.nih.gov/gene/24842",
      "https://www.nature.com/articles/s41467-025-66109-9_reference.pdf",
      "https://www.ncbi.nlm.nih.gov/gene/6777",
      "https://www.ncbi.nlm.nih.gov/gene/100133941",
      "https://www.nature.com/articles/s42003-025-09270-7",
      "https://www.nature.com/articles/s41467-025-65476-7",
      "https://www.nature.com/articles/s41698-025-01190-3",
      "https://www.ncbi.nlm.nih.gov/gene/7852",
      "https://www.ncbi.nlm.nih.gov/gene/29302",
      "https://www.ncbi.nlm.nih.gov/gene/146713",
      "https://www.nature.com/articles/s41598-025-30291-z",
      "https://www.nature.com/articles/s42003-025-08959-z",
      "https://www.ncbi.nlm.nih.gov/gene/596",
      "https://www.nature.com/articles/s41598-025-30853-1",
      "https://www.ncbi.nlm.nih.gov/gene/283",
      "https://www.nature.com/articles/s41467-025-67166-w_reference.pdf",
      "https://www.ncbi.nlm.nih.gov/gene/581",
      "https://www.ncbi.nlm.nih.gov/gene/675",
      "https://www.ncbi.nlm.nih.gov/gene/1029",
      "https://www.nature.com/articles/s41698-025-01151-w",
      "https://www.ncbi.nlm.nih.gov/gene/24387",
      "https://www.ncbi.nlm.nih.gov/gene/12578",
      "https://www.nature.com/articles/s41593-025-02123-w",
      "https://www.ncbi.nlm.nih.gov/gene/4323",
      "https://www.nature.com/articles/s41698-025-01152-9",
      "https://www.ncbi.nlm.nih.gov/gene/8842",
      "https://www.nature.com/articles/s41598-025-30888-4",
      "https://www.ncbi.nlm.nih.gov/gene/10631",
      "https://www.ncbi.nlm.nih.gov/gene/54209",
      "http://json-schema.org/draft-07/schema#\","
    ],
    "duration_seconds": 272.08543586730957
  }
}